Research on the molecular targets that drugs act on. Covers new antibiotic mechanisms, drug discovery competitions, bile-acid pathways, and Alzheimer's targets.
Research suggests that structural changes in upper motor neurons send a signal to immune cells, leading to toxic effects on neurons and reduced synaptic connections. Blocking inflammation with a semi-synthetic drug can restore synaptic connections and improve ALS symptoms.
Researchers at Tokyo Medical and Dental University characterize myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) using multiomics approaches, revealing distinct molecular features. This work provides crucial details for accurate diagnoses and therapeutic decisions.
Scientists have mapped neuroblastoma tumors at the cell level and discovered a brake on the immune system that can be blocked with existing immunotherapy. A new combination treatment targeting TIGIT and PD-L1 is being developed, showing promising results in lab experiments.
Researchers have discovered a brain circuit that mediates panic disorder, consisting of specialized neurons that send and receive the neuropeptide PACAP. Inhibiting PACAP signaling reduces panic symptoms, offering promising findings for future treatments.
Researchers at Icahn School of Medicine at Mount Sinai developed a novel genetic priority score (GPS) to integrate various types of human genetic data for easy target prioritization. The tool identifies genes with high potential for clinical trial success, particularly those with demonstrated genetic support.
Researchers uncovered insights into TAAR1's mechanism of action, highlighting significant differences between human and rodent models. The study suggests species-specific differences in drug-receptor interactions, paving the way for improved medications targeting substance use disorders.
Researchers have developed a novel method to produce a selective anticancer precursor substance. The synthesis involves the reaction of metal-active oxygen species with nitrile, utilizing cost-effective metals at lower temperatures. This breakthrough opens up new possibilities in developing innovative drugs against cancer.
A clinical trial found that diosmin reduced swelling at the knee, calf, and thigh up to 14 days after TKA, with lower pain scores on movement. The study also showed improved outcomes for short-term complications and a trend toward decreased postoperative nausea and vomiting.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
A novel inhibitor drug, KRB-456, has been discovered to target the KRAS G12D mutation in pancreatic cancer patient-derived tumors. The study demonstrates that KRB-456 significantly inhibits tumor growth in mice, offering a promising therapeutic option for KRAS-driven cancers.
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
Klick Applied Sciences unveils LOVENet, an AI framework that rapidly identifies new therapeutic indications for existing drugs. The algorithm integrates large language model and structured knowledge graph technology to offer a fresh perspective on new potential applications.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
A new study found that deaths from infective endocarditis decreased overall in the US, but rose sharply among people ages 25-44, likely linked to the opioid crisis. Researchers call for more investigation into the trends and recommend comprehensive care plans including substance use disorder screening and treatment.
Researchers found that BCMA-positive extracellular vesicles (EVs) in plasma levels correlated with myeloma patient responses to belantamab-mafodotin therapy. High EV levels preceded FLC progression and were associated with mafodotin-induced eryptosis.
A Mayo Clinic study found that patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and decreased risk of blood clots. The use of warfarin was associated with a 32% reduction in mortality risk, making it an effective treatment for these patients.
Research suggests that anti-obesity medications can lower the risk of premature death in people with knee or hip osteoarthritis, particularly those who experience a slow-to-moderate rate of weight loss. Studies show a 28% lower risk of death for these individuals compared to those with no weight loss.
Researchers analyzed data from the Centers for Medicare and Medicaid Services and found that some private insurers were reimbursing pharmacies at much higher rates than what they spent to acquire generic drugs. This can lead to higher out-of-pocket costs for seniors due to copayments and deductibles.
According to a new study published in Annals of Internal Medicine, most adults who qualify for statin use for primary prevention are not receiving them. The study found that despite increased overall statin use over time, only 35% of eligible adults were taking statins between 2013 and 2018. The researchers suggest that innovative effo...
Researchers at UC Davis Comprehensive Cancer Center have shown that inhibiting galectin 1 protein using gene therapy can shrink liver cancer in mice, improving the anti-cancer immune response and increasing killer T cells. This approach has potential as a treatment for HCC prevention.
Temperature-sensitive emulsions offer a new method to control when droplets dissolve, enabling precise targeting of medicines to specific areas in the body. The discovery could revolutionize methods of delivering medication in higher concentrations to diseased areas.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
Scientists at St. Jude Children's Research Hospital identified genes directly regulated by the oncogenic HOXA9 protein in high-risk pediatric leukemias. The study found two major targets, FLT3 and CDK6, which can be therapeutically targeted with drugs, showing promising outcomes in preclinical models. Additionally, researchers discover...
Researchers at UCSF and Kaiser Permanente Washington found that participants who received personalized coaching experienced a 74% improvement in cognitive testing compared to non-intervention participants. The study also showed improvements in risk factors and quality of life, with modest but significant increases in cognitive function.
A team of researchers from Kyoto University found that the pituitary vasopressin system is crucial for building a robust circadian clock in the suprachiasmatic nucleus. This discovery has led to the development of potential treatments for jet lag, which currently target only the suprachiasmatic nucleus.
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
Researchers at University of California - San Francisco find that sense of taste signals brain to slow down eating. Using advanced techniques, they recorded brain activity in awake mice and found PRLH neurons controlled by mouth signals when eating normally, not gut signals as previously thought.
A team of researchers at Weill Cornell Medicine used an AI-based approach to uncover patterns among social determinants of health and their impact on children's health outcomes. The analysis found statistical associations between four broad patterns in social determinants and outcomes relating to child developmental health.
Researchers have identified a potential treatment for lower back pain by targeting senescent osteoclasts in the vertebral column of mice. Using anti-senescent drugs like Navitoclax may relieve spinal sensitivity and reduce pain, according to the study published in eLife.
A three-year intensive treatment strategy to lower systolic blood pressure below 120mmHg significantly reduced cardiovascular events, including heart attack, stroke, and death, compared to standard treatment. The study found that participants in the intensive group experienced fewer major vascular events and deaths over a two-year period.
A new study by Cleveland Clinic researchers reveals significant differences in cell communication between breast tissue with and without BRCA1/2 gene mutations. This discovery provides a foundation for personalized medicine approaches to prevent and treat breast cancer in mutation carriers.
A new resorbable scaffold has been shown to be more effective than traditional angioplasty in treating severe artery blockages in the lower leg. In a large clinical trial, patients who received the scaffold had a 74% chance of avoiding adverse events, compared to 44% for those who underwent angioplasty.
A single infusion of CRISPR-based gene-editing therapy significantly reduced LDL cholesterol levels in people with heterozygous familial hypercholesterolemia, a condition that increases heart attack risk. The treatment has shown potential as a long-term or permanent option for high LDL-C control.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
A new anti-clotting medication, abelacimab, has significantly reduced bleeding among people with atrial fibrillation who are at risk of stroke. The AZALEA-TIMI 71 trial found that abelacimab substantially reduced bleeding compared to the current standard of care use of direct-acting oral anticoagulants.
A four-year blood-pressure intervention significantly reduced the risk of developing dementia among adults with high blood pressure, compared to those who received usual care. The study found that lowering systolic blood pressure to less than 130 mm Hg and diastolic blood pressure to less than 80 mm Hg reduced dementia risk.
The C-Path Neuroscience Annual Workshop brought together stakeholders to chart a transformative course for neurology research and drug development, focusing on chronic progressive diseases such as Alzheimer's and Parkinson's. Key highlights included recommendations for innovative therapies and tools to address complex disorders.
Researchers discovered narrow-spectrum Wnt signaling inhibitors can suppress breast cancer tumors and reduce chemo-resistant cells in mice. The treatment, derived from a bacterial toxin, targets specific receptors to minimize bone density side effects.
A recent study found that transmucosal dose of buprenorphine followed by extended-release buprenorphine injection significantly reduced Clinical Opioid Withdrawal Scale scores in individuals using fentanyl. This rapid treatment strategy may be an important potential option for addressing the growing opioid crisis.
A study published in Nature Communications reveals that the 'salience network' in the brain is uniquely activated by intravenous drug use, which may be associated with higher addiction rates and faster relief from withdrawal. This finding could lead to the development of new therapies for substance use disorders.
The American Gastroenterological Association suggests a balanced approach when treating patients on GLP-1 RAs undergoing endoscopic procedures. AGA recommends proceeding with the procedure as planned for patients who followed standard pre-procedure fasting instructions and do not have symptoms suggesting retained gastric contents.
Researchers at Texas A&M University have found a correlation between flavonoid compounds and reduced endometriosis symptoms. Flavonoids like Quercetin and Kaempferol show promise in easing inflammation, with studies suggesting they may help suppress the symptoms of inflammatory diseases like endometriosis.
Scientists have created a method to keep targeted particles cool, allowing safe trapping of living cells in their native fluids. This advancement could help overcome problems with current laser light tweezers and enable targeted drug delivery applications.
Research identifies specific gut bacteria that increase risk of severe malaria in humans and mice, sparking new approaches targeting gut microbiota. The study's findings could lead to prevention strategies for severe malaria-related deaths.
A new study finds that certain gut-dwelling fungi amplify excessive inflammation in severe COVID-19 and cause long-lasting changes in the immune system. Patients with these fungi may benefit from specialized treatments targeting the fungi or immunological changes they instigate.
A study led by UC San Francisco found that homeless individuals have a 7 times higher rate of sudden cardiac death compared to the general population. Non-cardiac causes, such as overdoses and unrecognized infections, are more common among homeless people.
A new neighborhood-based care model has been shown to be effective in treating hepatitis C among injection drug users and those experiencing homelessness. The study found that 92% of participants had undetectable levels of the virus after treatment, with 84% achieving sustained virologic response.
Researchers at Hokkaido University identified 2-thiouridine as a broad-spectrum antiviral drug candidate targeting ssRNA+ viruses. It inhibits viral replication and increases survival rates in mice models for dengue and COVID-19.
Researchers are testing a single target to weaken tumors and strengthen immune cells in pediatric brain tumor patients. The goal is to improve the effectiveness of CAR-T therapy, which has shown promise but also leads to exhaustion of immune cells.
Researchers discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy. Cancer cells respond to radiation by rewiring metabolic signaling pathways using lactic acid instead of glucose.
Researchers at H. Lee Moffitt Cancer Center & Research Institute demonstrate lorlatinib's activity against protein PYK2 in non-small cell lung cancer cells, revealing a potential path for repurposing the drug for other cancers. The study shows that combination therapy targeting ROS1, PYK2, and SRC results in enhanced cancer cell death ...
Researchers at UCSF found a feedback loop between immune protein IL-31 and nerve cells, which dials back nearby inflammation and promotes skin healing. This discovery could lead to new treatments for conditions like eczema, allergies, and asthma by targeting the nervous system's role in regulating the immune response.
Researchers at Queen Mary University of London developed a new organ-on-a-chip model of the human synovium to study arthritis mechanisms and develop new treatments. The three-dimensional microfluidic device successfully replicates key features of native synovium biology.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
Researchers identified YB-1 as an attractive therapeutic target for pleural mesothelioma, a cancer caused by asbestos exposure. Indirect targeting of YB-1 via histone deacetylase inhibitors showed promise in enhancing chemo- and radiotherapy sensitivity.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
Researchers at the University of Virginia Health System are developing computer models to better understand the cellular processes and gene activity of multi-drug resistant bacteria Staphylococcus aureus and Pseudomonas aeruginosa. The goal is to identify vulnerabilities in these bacteria and advance the development of new treatments.
A study found that people with a specific genetic mutation in the CARD9 gene have higher IL-17 protein levels, making them more responsive to IL-17 inhibitor biologics. This discovery may lead to targeted treatment recommendations for ankylosing spondylitis patients.
A study of over 850,000 Australian children born between 2009 and 2017 found a small increased risk of birth defects among those conceived through fertility treatment, partly attributed to parental infertility. The use of intracytoplasmic sperm injection (ICSI) was also associated with an increased risk for genitourinary abnormalities.